NEUREN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.27 AUD | +3.15% |
|
+6.35% | -14.82% |
| 05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
| 05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
Presenter SpeechGerry Zhao (Executives)Good morning, all. Welcome to Neuren's investor webinar...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Companyâs product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
20.62
AUD
Average target price
28.56
AUD
Spread / Average Target
+38.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.82% | 1.75B | |
| +55.95% | 819B | |
| +43.22% | 638B | |
| -6.98% | 351B | |
| +19.08% | 329B | |
| +9.05% | 298B | |
| +17.21% | 242B | |
| +2.58% | 225B | |
| +13.28% | 217B | |
| +8.91% | 168B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Transcript : Neuren Pharmaceuticals Limited - Special Call
